Indirubin-3′-oxime derivatives as potent cyclin dependent kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8859783
APP PUB NO 20120295948A1
SERIAL NO

13576105

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ANYGEN CO LTDRM 301C NANO BIO RESEARCH CENTER SAN 109 SAMTAE-RI NAM-MYUN JANGSEONG-GUN JEOLLANAM-DO 515-893

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ban, Soo-Ho Gwangju, KR 1 4
Choi, Soo-Jeong Gyeongsangnam-do, KR 2 23
Jeong, Soon-Young Gwangju, KR 1 4
Kim, Jae-Il Gwangju, KR 56 414
Kim, Yong-Chul Gwangju, KR 67 500
Lee, Jung-Eun Seoul, KR 66 413

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 14, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00